Corcept Therapeutics (CORT) Change in Receivables (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Change in Receivables data on file, last reported at -$20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 364.11% year-over-year to -$20.7 million; the trailing twelve-month figure through Mar 2026 stood at -$22.7 million (down 7657.14% YoY), and the FY2025 full-year result was $5.8 million, down 54.8% from the prior year.
• Change in Receivables slipped to -$20.7 million in Q1 2026, from -$9.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.4 million in Q1 2024 to a low of -$20.7 million in Q1 2026.
• A 5-year average of $673352.9 and a median of $1.5 million in 2023 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 1259.67% in 2024, while the deepest fall reached 191925.0% in 2024.
• Tracing CORT's Change in Receivables over 5 years: stood at $1.6 million in 2022, then jumped by 295.44% to $6.5 million in 2023, then tumbled by 188.36% to -$5.7 million in 2024, then plunged by 71.45% to -$9.8 million in 2025, then slumped by 110.44% to -$20.7 million in 2026.
• Business Quant data shows CORT's Change in Receivables at -$20.7 million in Q1 2026, -$9.8 million in Q4 2025, and $5.1 million in Q3 2025.